Deciphera to Acquire UroGen Pharma for $750M
Ticker: URGN · Form: 8-K · Filed: Jun 13, 2025 · CIK: 1668243
| Field | Detail |
|---|---|
| Company | Urogen Pharma Ltd. (URGN) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, merger, healthcare, oncology
Related Tickers: DCPH
TL;DR
Deciphera is buying UroGen for $750M cash, deal expected Q3 2025.
AI Summary
UroGen Pharma Ltd. announced on June 12, 2025, that it has entered into a definitive agreement to be acquired by Deciphera Pharmaceuticals, LLC. The transaction is valued at approximately $750 million, with Deciphera acquiring all outstanding shares of UroGen for $17.10 per share in cash. This acquisition is expected to close in the third quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition significantly consolidates the uro-oncology space, potentially impacting future treatment options and market competition for bladder cancer therapies.
Risk Assessment
Risk Level: medium — The deal is subject to customary closing conditions and regulatory approvals, which could delay or prevent its completion.
Key Numbers
- $750M — Acquisition Value (Total cash consideration for UroGen Pharma)
- $17.10 — Per Share Price (Cash amount each UroGen shareholder will receive)
Key Players & Entities
- UroGen Pharma Ltd. (company) — Registrant
- Deciphera Pharmaceuticals, LLC (company) — Acquiring entity
- $750 million (dollar_amount) — Acquisition valuation
- $17.10 (dollar_amount) — Per share acquisition price
- June 12, 2025 (date) — Date of agreement
- Third quarter of 2025 (date) — Expected closing period
FAQ
What is the primary reason for Deciphera acquiring UroGen Pharma?
While not explicitly stated in this 8-K, the acquisition likely aims to expand Deciphera's portfolio in uro-oncology, leveraging UroGen's assets and pipeline.
What is the total value of the transaction?
The transaction is valued at approximately $750 million.
What is the price per share for UroGen shareholders?
UroGen shareholders will receive $17.10 per share in cash.
When is the acquisition expected to be completed?
The acquisition is expected to close in the third quarter of 2025.
Are there any specific conditions that must be met for the deal to close?
Yes, the transaction is subject to customary closing conditions and regulatory approvals.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding UroGen Pharma Ltd. (URGN).